PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Closed-Loop Digital Framework Cuts Controlled Substance Documentation Gaps

controlled substancesnarcotic drugsclass 1 psychotropicsmedication safetyclosed-loop managementbarcode medication administrationbatch traceabilityempty-ampoule recoverydiversion preventionquality improvementhealth informaticsHIMSS EMRAMpre-post study Medication Safety

Background Information

Improving controlled substance safety with a 3D closed-loop framework.

Controlled substances require meticulous management to ensure safety and compliance in healthcare settings. Prescription dispensing record compliance increased from 94.82% to 98.7%, and batch-number management noncompliance decreased from 2.4% to 0.6%. The 3D closed-loop framework showed significant improvements in controlled substance management but requires further multicenter validation for broader application. The framework enhanced controlled substance management in a digitally mature hospital, warranting further testing for broader use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Sun N, Su J, Yu Q, Xu Y, Zhuo M

Citation: Sun N, Su J, Yu Q, et al. A Quantifiable 3D Closed-Loop Framework for Controlled Substance Safety in a HIMSS Electronic Medical Record Adoption Model (EMRAM) Stage 7 Hospital: Pre-Post Quality Improvement Study. JMIR medical informatics. 2026;14:e98247. doi:10.2196/98247

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →